STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

NCT03829371 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Velcade
DRUG: Melphalan
DRUG: Prednisone
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Daratumumab

Sponsor

University of Turin, Italy